2024
Burden of Ischemic Heart Disease and Its Attributable Risk Factors in North Africa and the Middle East, 1990 to 2019: Results From the GBD Study 2019
Aminorroaya A, Moghaddam S, Tavolinejad H, Aryan Z, Heidari B, Ebrahimi H, Naderian M, Shobeiri P, Ghanbari A, Rezaei N, Malekpour M, Haghshenas R, Rezaei N, Larijani B, Farzadfar F. Burden of Ischemic Heart Disease and Its Attributable Risk Factors in North Africa and the Middle East, 1990 to 2019: Results From the GBD Study 2019. Journal Of The American Heart Association 2024, 13: e030165. PMID: 37956220, PMCID: PMC10926818, DOI: 10.1161/jaha.123.030165.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsBurden of ischemic heart diseaseDisability-adjusted life year ratesRates of ischemic heart diseaseIschemic heart diseaseRisk factorsMortality of ischemic heart diseaseEpidemiology of ischemic heart diseaseIschemic heart disease burdenHigh low-density lipoprotein cholesterolDietary risk factorsLost disability-adjusted life yearsYears of lifeHeart diseaseGBD studyPremature mortalityLow-density lipoprotein cholesterolSystolic blood pressureHighest burdenMetabolic riskBehavioral risksLife yearsPremature deathContemporary epidemiologyLipoprotein cholesterol
2021
Atomoxetine as an adjunct to nonpharmacological treatments for preventing vasovagal attacks in patients with recurrent vasovagal syncope: A pilot randomized-controlled trial
Tajdini M, Aminorroaya A, Tavolinejad H, Tofighi S, Jalali A, Sadeghian S, Vasheghani-Farahani A, Yadangi S, Shahmansouri N, Akhondzadeh S, Bozorgi A. Atomoxetine as an adjunct to nonpharmacological treatments for preventing vasovagal attacks in patients with recurrent vasovagal syncope: A pilot randomized-controlled trial. IJC Heart & Vasculature 2021, 34: 100789. PMID: 34027030, PMCID: PMC8129927, DOI: 10.1016/j.ijcha.2021.100789.Peer-Reviewed Original ResearchPre-syncopal episodesRecurrent vasovagal syncopeVasovagal syncopeEffects of atomoxetinePrimary endpointPlacebo groupMedian timeSubgroup analysis of patientsPre-syncopal attackNorepinephrine reuptake inhibitionPlacebo-controlled trialAnalysis of patientsPharmacological treatment optionsSystolic blood pressureDiagnosed VVSSyncope/pre-syncopeReduced quality of lifeReuptake inhibitionRandomized patientsAtomoxetine groupSyncopal episodesVasovagal attackTreatment optionsSubgroup analysisRandomized trials